April 7, 2025 11:00 AM EDT

Immunology startup RayThera secures $110M in Series A raise

Ayisha Sharma

News Reporter

RayThera has collected $110 million in a Series A raise to help it advance a preclinical pipeline of small molecule drugs for immunological diseases. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Immunology startup RayThera secures $110M in Series A raise

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Merck KGaA closes in on SpringWorks deal at $3.5B price point

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Im­munol­o­gy start­up RayThera se­cures $110M in Se­ries A raise

News Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Immunology startup RayThera secures $110M in Series A raise